Market Place
Sourcing Support
Lecanemab Long-Term Real-World Data Revealed At 2026 AD/PD
23 Mar 2026 //
PR NEWSWIRE
Lecanemab Long-Term Real-World Data to Be Presented at AD/PD 2026
11 Mar 2026 //
PR NEWSWIRE
Eisai Seeks EMA Approval For Leqembi IV Maintenance Dosing
26 Jan 2026 //
PR NEWSWIRE
BLA For Subcutaneous Formulation Of Leqembi Accepted In China
06 Jan 2026 //
PR NEWSWIRE
Leqembi Data Shows Potential 8.3 Year Disease Delay
04 Dec 2025 //
PR NEWSWIRE
TIME Selects Leqembi-Iqlik As Top Innovation Of 2025
14 Oct 2025 //
PR NEWSWIRE
First Patient Treated With Leqembi® (Lecanemab) In The Nordics
14 Oct 2025 //
PR NEWSWIRE
Leqembi Iqlik Maintenance Treatment Launched In U.S.
06 Oct 2025 //
PR NEWSWIRE
Lecanemab Approval For Alzheimer`s Treatment In Australia
24 Sep 2025 //
GLOBENEWSWIRE
FDA Begins sBLA for Leqembi® Iqlik as Early Alzheimer`s Treatment
02 Sep 2025 //
PR NEWSWIRE
FDA Approves Leqembi IQKLIK Injection for Early Alzheimer
30 Aug 2025 //
PR NEWSWIRE
Novartis, BioArctic Partner To Penetrate the Blood-Brain Barrier
29 Aug 2025 //
BIOSPACE
Novartis pens BioArctic neuro pact worth $30M upfront
27 Aug 2025 //
FIERCE BIOTECH
Novartis, BioArctic Partner on BrainTransporter for Neurology
26 Aug 2025 //
EXPRESSPHARMA
BioArctic and Novartis Ink BrainTransporter™ Deal for $30M
26 Aug 2025 //
PR NEWSWIRE
Leqembi® (lecanemab) launched in the EU today
25 Aug 2025 //
PR NEWSWIRE
Leqembi® Q2 2025 Sales Reach 23.1 Billion Yen
31 Jul 2025 //
PR NEWSWIRE
AAIC 2025 to Feature Lecanemab`s Four-Year Efficacy and Safety
22 Jul 2025 //
PR NEWSWIRE
Lecanemab Drug Discovery Wins 9th Bioindustry Award in Japan
16 Jul 2025 //
PR NEWSWIRE
BioArctic to Start New Cohorts in Exidavnemab Phase 2a Study
13 Jun 2025 //
PR NEWSWIRE
Eisai Forecasts Leqembi® Revenue at JPY 76.5 Billion in 2025
15 May 2025 //
PR NEWSWIRE
BioArctic`s Q1 Report Presentation on May 21
13 May 2025 //
PR NEWSWIRE
EU Commission refers lecanemab decision to Appeal Committee
01 Apr 2025 //
PR NEWSWIRE
TGA Declines Registration Of Lecanemab In Australia
03 Mar 2025 //
PR NEWSWIRE
BioArctic`s global license agreement with Bristol Myers Squibb
20 Feb 2025 //
PR NEWSWIRE
Update On Regulatory Review Of Lecanemab In EU For Alzheimer`s
31 Jan 2025 //
PR NEWSWIRE
FDA Accepts LEQEMBI BLA for Subcutaneous Maintenance Dosing for AD
13 Jan 2025 //
PR NEWSWIRE
BioArctic Signs Global License with Bristol Myers Squibb
19 Dec 2024 //
PR NEWSWIRE
1st patient dosed in EXIST Phase 2a study in Parkinson`s disease
05 Dec 2024 //
PR NEWSWIRE
Leqembi® approved in Mexico
04 Dec 2024 //
PR NEWSWIRE
Leqembi® launched in South Korea
27 Nov 2024 //
PR NEWSWIRE
CHMP Recommends Approval of Lecanemab in the EU
14 Nov 2024 //
PR NEWSWIRE
Eisai Upgrades Leqembi Sales Forecast To JPY 42.5 bn For Fis 2024
07 Nov 2024 //
PR NEWSWIRE
BioArctic Invites Q3 2024 Report Presentation on November 14
06 Nov 2024 //
PR NEWSWIRE
BrainTransporter™ Enhances Antibody Delivery to the Brain
06 Nov 2024 //
PR NEWSWIRE
Lecanemab Data at CTAD: Early Initiation & Long-Term Benefits
31 Oct 2024 //
PR NEWSWIRE
Leqembi® revenue totaled JPY 10 billion in the third quarter 2024
30 Oct 2024 //
PR NEWSWIRE
Lifetime Achievement Award, lecanemab and biomarkers at CTAD Conf
24 Oct 2024 //
PR NEWSWIRE
Eisai To Request Reconsideration Of Lecanemab In Australia
16 Oct 2024 //
PR NEWSWIRE
Eisai Initiates Leqembi Rolling BLA For Subcutaneous Maintenance Dosing
14 May 2024 //
PR NEWSWIRE
BioArctic, Eisai Sign BAN2802 Research Evaluation Agreement
20 Apr 2024 //
PR NEWSWIRE
Submission of Leqembi® sBLA for the treatment of early AD to the FDA completed
31 Mar 2024 //
PR NEWSWIRE
BioArctic: New data on lecanemab presented at the 2024 AD/PD™ congress
11 Mar 2024 //
PR NEWSWIRE
The EMA`s SAG to discuss the MAA for lecanemab: BioArctic
11 Jan 2024 //
PR NEWSWIRE
BioArctic receives patent in Japan for antibodies targeting Parkinson`s disease
23 Aug 2023 //
PR NEWSWIRE
Latest data on lecanemab to be presented at AAIC 2023
11 Jul 2023 //
PR NEWSWIRE
Marketing Authorisation Application for lecanemab submitted in Great Britain
21 May 2023 //
PR NEWSWIRE
Societal value of lecanemab in Japan published in Neurology and Therapy
17 May 2023 //
PR NEWSWIRE
BioArctic: New lecanemab-data presented at AD/PD 2023
03 Apr 2023 //
PR NEWSWIRE
BioArctic hires Anders Martin-Löf as new CFO
28 Feb 2023 //
PR NEWSWIRE
BioArctic: Lecanemab receives priority review status in Japan
29 Jan 2023 //
PR NEWSWIRE
EMA accepts MAA for lecanemab as treatment for Alzheimer`s disease: BioArctic
26 Jan 2023 //
PR NEWSWIRE
BioArctic`s partner Eisai submits MAA for lecanemab for Alzheimer`s disease
10 Jan 2023 //
PR NEWSWIRE
FDA approves LEQEMBI under the Accelerated Approval pathway
09 Jan 2023 //
PR NEWSWIRE
Eisai submits supplemental BLA to FDA for traditional approval of LEQEMBI
08 Jan 2023 //
PR NEWSWIRE
